Table 3 Participant details of participants included in the clustering analyses

Age

16.62 ± 5.69

7.47–29.57

15.45 ± 6.52

6.23–28.74

16.72 ± 6.23

7.55–29.84

14.44 ± 4.82

7.68–27.11

VIQ

109.22 ± 16.13

66–160

85.6 ± 17.38

45–121

113.81 ± 13.98

89–160

96.25 ± 25.66

51–138

PIQ

109.27 ± 15.15

75–148

88 ± 20.27

53–132

111.77 ± 13.25

85–136

93.67 ± 25.9

49–139

ADOS

4.69 ± 2.43

1–9

6.84 ± 2.54

2–10

N/A

N/A

SRS

69.33 ± 12.7

44–90

77.33 ± 10.46

53–90

44.31 ± 5.69

37–66

51.68 ± 12.75

38–76

RBS

14.22 ± 12.87

0–54

24.03 ± 15.46

1–60

1.06 ± 2.49

0–12

3.42 ± 5.36

0–17

VABS-2

78.75 ± 15.43

20–110

66.82 ± 20.25

20–115

123.5 ± 9.69

117–141

51.25 ± 31.6

28–96

Sex m:f

51:32

29:7

40:26

20:4

ID participants

1 (1.2%)

10 (27.7%)

0 (0%)

8 (33.3%)

Neuropsychiatric symptoms*

29 (34.9%)

17 (47.2%)

0 (0%)

3 (12.5%)

ID + Neuropsychiatric symptoms*

0 (0%)

5 (13.9%)

0 (0%)

3 (12.5%)

Medication use

39

18

11

6